STAT News
NOVEMBER 3, 2022
The early-stage study, which is being sponsored by BioNTech, aims to evaluate safety, tolerability, and immunogenicity, or the ability to generate an immune response. The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.
XTalks
OCTOBER 16, 2020
Ebola virus is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, as well as with surfaces and materials – such as bedding and clothing – contaminated with these fluids.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 22, 2022
The phase 1 clinical trial will evaluate the safety and immune response of the vaccine in healthy individuals at the Kaiser Permanente Washington Health Research Institute in Seattle, the article detailed.
XTalks
MARCH 11, 2025
Emerging evidence indicates that a multivalent mRNA vaccine encoding hemagglutinin antigens from all known influenza virus subtypes can elicit broad, cross-reactive antibody responses in animal models, demonstrating the potential of mRNA platforms to overcome challenges posed by antigenically variable viruses.
XTalks
SEPTEMBER 14, 2020
It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial.
Expert insights. Personalized for you.
97 
Let's personalize your content